Despite reporting lower-than-expected revenue for 2024, Hutchmed (NASDAQ:HCM) traded higher on Wednesday after the Chinese ...

In February 2025 in Lynn, Massachusetts, ICE grabbed an 18-year-old high school junior from Nicaragua and put her in a cell ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows ...

We’ve lowered our fair value estimate to $125 per share from $135 to account for Crown's plan to divest its fiber and small cell business for $8.5 billion. Our fair value estimate implies enterprise ...

With Its Science-backed Products And Global Celebrity Following, Augustinus Bader Is Transforming The Skincare Wardrobes Of ...

With Its Science-backed Products And Global Celebrity Following, Augustinus Bader Is Transforming The Skincare Wardrobes Of ...

("Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer ...

Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Researchers discovered that epithelial cells that line human skin are able to communicate danger to the body through a silent ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.